esculin + digitalis glycosides

Esculin + digitalis glycosides is a fixed-dose combination ophthalmic preparation containing esculin (a coumarin glucoside) and digitalis glycosides (cardiac glycoside compounds derived from Digitalis species). This combination is formulated as eye drops for topical ocular use. Esculin possesses anti-inflammatory and antioxidant properties, while digitalis glycosides are thought to provide neuroprotective effects in the retina. The mechanism of action in ophthalmology appears to involve reduction of inflammation, oxidative stress, and possibly improvement of microcirculation or retinal function. The product has been studied primarily for dry eye disease (DED), visual acuity recovery after refractive surgery, asthenopia (eye strain), prevention/treatment of diabetic retinopathy, macular degeneration, conjunctivitis (including allergic forms), optic neuritis, retinitis, eyestrain-related symptoms involving muscle/nerv/adaptive fatigue, and pterygium. Clinical studies suggest efficacy in improving subjective symptoms such as discomfort or dryness as well as objective measures like tear production or visual acuity[1][2][3][5]. No significant safety concerns have been reported in short-term studies.

Brand names

Esculin and Digitalis Glycosides Eye Drops

Other names

EAD eye dropsesculin and digitalisglycosides eye drops